149
iatrogénicas e reduzindo o tempo cirúrgico. O “timing” e a dose
ideal do fármaco ainda não estão totalmente definidos mas um inter-
valo inferior a 7 dias parece reduzir o risco de induzir ou agravar um
descolamento tracional da retina.
Bibliografia
1.
Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avas-
tin) in the treatment of proliferative diabetic retinopathy. Ophthalmology
2006;113:1695
e705. e1e15.
2.
Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in
active progressive proliferative diabetic retinopathy. Graefes Arch Clin
Exp Ophthalmol 2008;246:1699e705.
3.
Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin)
for persistent new vessels in diabetic retinopathy (IBEPE study). Retina
2006;26:1006
e13.
4.
Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative
adjunct for tractional retinal detachment repair in severe proliferative dia-
betic retinopathy. Retina 2006;26:699e700.
5.
Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for
prevention of early postvitrectomy hemorrhage in diabetic patients: a ran-
domized clínical trial. Ophthalmology 2009;116:1943e8.
6.
Yeh PT, Yang CM, Lin YC, et al. Bevacizumab pretreatment in vitrectomy
with silicone oil for severe diabetic retinopathy. Retina 2009;29:768e74.
7.
Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal
bevacizumab (Avastin) as a preoperative adjunct before vitrectomy sur-
gery in the treatment of severe proliferative diabetic retinopathy (PDR).
Graefes Arch Clin Exp Ophthalmol 2008;246:837e42.
8.
Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal beva-
cizumab (Avastin). Ophthalmology 2007;114:855e9.
9.
Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizu-
mab through the retina after intravitreal injection in the monkey. Invest
Ophthalmol Vis Sci 2007;48:2814e23.
10.
di Lauro R, De Ruggiero P, di Lauro R, et al. Intravitreal bevacizumab
for surgical treatment of severe proliferative diabetic retinopathy. Graefes
Arch Clin Exp Ophthalmol 2010;248:785e91
11.
Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in
active progressive proliferative diabetic retinopathy. Graefes Arch Clin
Exp Ophthalmol 2008;246:1699e705.
12.
Ishikawa K, Honda S, Tsukahara Y, et al. Preferable use of intravitreal
bevacizumab as a pretreatment of vitrectomy for severe proliferative dia-
betic retinopathy. Eye (Lond) 2009;23:108e11.
13.
Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative